Table 1. Clinical and laboratory data of... | American Society of Hematology

Table 1.

Clinical and laboratory data of the patients studied

Patient no.	Sex	Age (y)	Disease^*	Duration (mo)	Previous medications	Antibody specificity^†	Bone marrow^‡	Peripheral blood counts^1-153
Patient no.	Sex	Age (y)	Disease^*	Duration (mo)	Previous medications	Antibody specificity^†	Cellularity	Hb (g/dL)	WBC (×10⁹/L)	Neutro (×10⁹/L)	Lympho (×10⁹/L)	Plt (×10⁹/L)	Ret (×10⁹/L)
1	F	52	Idiopathic AIN	60	G-CSF	ND	Increased/hypercellular myeloid series with normal maturation	12.3	1.2	0.5	0.3	165	46
2	F	58	AIN/Sjogren	12	None	ND	Normal/normal myeloid series	10.8	1.9	0.8	0.8	152	45
3	F	20	AIN/thyroiditis	15	G-CSF	anti-NA1	Normal/normal myeloid series	13.8	2.0	0.2	1.2	250	55
4	F	25	Idiopathic AIN	7	None	anti-NA1	Increased/hypercellular myeloid series with left shift	10.5	2.3	0.7	1.4	154	45
5	F	19	Idiopathic AIN/ pancytopenia	66	PDN/γ-globulin	anti-NA1	Increased/hypercellular myeloid series with left shift, increased Meg series	8.9	3.6	0.7	1.7	140	55
5	F	19	Idiopathic AIN/ pancytopenia	66	PDN/γ-globulin	anti-GPV		8.9	3.6	0.7	1.7	140	55
6	M	35	Idiopathic AIHA	8	PDN/γ-globulin		Markedly increased/hypercellular erythroid and Meg series	12.9	6.1	3.3	2.2	360	114
7	M	46	ITP/AIHA	48	PDN/AZA	anti-GPIIb/IIIa	Mildly increased/hyperplasia of Meg series	12.0	7.5	4.5	1.6	63	65
7	M	46	ITP/AIHA	48	γ-globulin	anti-GPIb/IX	Mildly increased/hyperplasia of Meg series	12.0	7.5	4.5	1.6	63	65
8	F	30	ITP	3	None	anti-GPIIb/IIIa	Mildly increased/hyperplasia of Meg series	16.0	5.0	2.4	1.9	94	50
9	F	24	ITP	28	PDN/AZA/CSA	anti-GPIb/IX	Mildly increased/hyperplasia of Meg series	12.0	2.7	1.9	0.4	87	60
					VCR/CAMPATH-1
					γ-globulin
10	F	20	ITP/AIHA/Behcet disease	84	PDN	ND	Normal/slightly increased Meg series	12.1	4.4	2.3	1.7	173	55
11	M	65	Primary PRCA^1-155	48	PDN/AZA/CSA		Normal/near absence of erythroid series, normal myeloid and Meg series	6.1	4.6	1.7	1.6	110	35
12	F	48	Primary PRCA^1-155	24	PDN/ALG/CSA		Normal/reduced erythroid series, normal myeloid and Meg series	11.6	5.6	3.4	1.8	255	18
13	M	30	Primary PRCA^1-155	36	PDN/CSA		Normal/near absence of erythroid series, normal myeloid and Meg series	8.9	4.3	2.5	1.7	333	20
14	F	34	Primary PRCA	24	PDN/CSA		Normal/absence of erythroid series, normal myeloid and Meg series	5.3	5.7	3.5	2.0	205	25
15	F	34	Primary PRCA	14	PDN/CSA		Normal/reduced erythroid series, normal myeloid and Meg series	8.4	5.9	3.7	1.9	335	25

Patient no.	Sex	Age (y)	Disease^*	Duration (mo)	Previous medications	Antibody specificity^†	Bone marrow^‡	Peripheral blood counts^1-153
Patient no.	Sex	Age (y)	Disease^*	Duration (mo)	Previous medications	Antibody specificity^†	Cellularity	Hb (g/dL)	WBC (×10⁹/L)	Neutro (×10⁹/L)	Lympho (×10⁹/L)	Plt (×10⁹/L)	Ret (×10⁹/L)
1	F	52	Idiopathic AIN	60	G-CSF	ND	Increased/hypercellular myeloid series with normal maturation	12.3	1.2	0.5	0.3	165	46
2	F	58	AIN/Sjogren	12	None	ND	Normal/normal myeloid series	10.8	1.9	0.8	0.8	152	45
3	F	20	AIN/thyroiditis	15	G-CSF	anti-NA1	Normal/normal myeloid series	13.8	2.0	0.2	1.2	250	55
4	F	25	Idiopathic AIN	7	None	anti-NA1	Increased/hypercellular myeloid series with left shift	10.5	2.3	0.7	1.4	154	45
5	F	19	Idiopathic AIN/ pancytopenia	66	PDN/γ-globulin	anti-NA1	Increased/hypercellular myeloid series with left shift, increased Meg series	8.9	3.6	0.7	1.7	140	55
5	F	19	Idiopathic AIN/ pancytopenia	66	PDN/γ-globulin	anti-GPV		8.9	3.6	0.7	1.7	140	55
6	M	35	Idiopathic AIHA	8	PDN/γ-globulin		Markedly increased/hypercellular erythroid and Meg series	12.9	6.1	3.3	2.2	360	114
7	M	46	ITP/AIHA	48	PDN/AZA	anti-GPIIb/IIIa	Mildly increased/hyperplasia of Meg series	12.0	7.5	4.5	1.6	63	65
7	M	46	ITP/AIHA	48	γ-globulin	anti-GPIb/IX	Mildly increased/hyperplasia of Meg series	12.0	7.5	4.5	1.6	63	65
8	F	30	ITP	3	None	anti-GPIIb/IIIa	Mildly increased/hyperplasia of Meg series	16.0	5.0	2.4	1.9	94	50
9	F	24	ITP	28	PDN/AZA/CSA	anti-GPIb/IX	Mildly increased/hyperplasia of Meg series	12.0	2.7	1.9	0.4	87	60
					VCR/CAMPATH-1
					γ-globulin
10	F	20	ITP/AIHA/Behcet disease	84	PDN	ND	Normal/slightly increased Meg series	12.1	4.4	2.3	1.7	173	55
11	M	65	Primary PRCA^1-155	48	PDN/AZA/CSA		Normal/near absence of erythroid series, normal myeloid and Meg series	6.1	4.6	1.7	1.6	110	35
12	F	48	Primary PRCA^1-155	24	PDN/ALG/CSA		Normal/reduced erythroid series, normal myeloid and Meg series	11.6	5.6	3.4	1.8	255	18
13	M	30	Primary PRCA^1-155	36	PDN/CSA		Normal/near absence of erythroid series, normal myeloid and Meg series	8.9	4.3	2.5	1.7	333	20
14	F	34	Primary PRCA	24	PDN/CSA		Normal/absence of erythroid series, normal myeloid and Meg series	5.3	5.7	3.5	2.0	205	25
15	F	34	Primary PRCA	14	PDN/CSA		Normal/reduced erythroid series, normal myeloid and Meg series	8.4	5.9	3.7	1.9	335	25

Hgb indicates hemoglobin; WBC, white blood cells; Neutro, neutrophils; Lympho, lymphocytes; Plt, platelets; Ret, reticulocytes; AIN, autoimmune neutropenia; AIHA, autoimmune hemolytic anaemia; ITP, autoimmune thrombocytopenic purpura; PRCA, pure red cell aplasia; Meg series, megakaryocytic series; G-CSF, granulocyte-colony stimulating factor; PDN, prednisone; AZA, azathioprine; CSA, cyclosporin A; VCR, vincristine; ALG, antilymphocyte globulin; ND, not defined; NA1, neutrophil antigen 1; GP, platelet glycoprotein.

AIN diagnosis was based on the presence of specific antineutrophil antibodies in patient serum detected with chemilumonescence and immunofluorescence techniques.23 ITP diagnosis was based on the presence of antiplatelet antigens or anti-GP specific antibodies in patient sera and platelets detected by means of flow cytometry (platelet flow cytometric immunofluorescence technique; PIFT) and ELISA (monoclonal antibody immobilization of platelet antigen assay; MAIPA).24

†

In cases of AIN and ITP.

‡

At diagnosis.

F1-153

Performed at the time of study.

F1-155

Bone marrow T-cell receptor and immunoglobulin gene rearrangement studies had been performed to exclude clonality.

View Large

This Feature Is Available To Subscribers Only